- Home
- Publications
- Publication Search
- Publication Details
Title
The Adjuvant Treatment of HER2-Positive Breast Cancer
Authors
Keywords
-
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 13, Issue 2, Pages 230-239
Publisher
Springer Nature
Online
2012-03-12
DOI
10.1007/s11864-012-0186-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer
- (2011) M. Elizabeth Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials
- (2010) Stuart D. Russell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
- (2009) Giuseppe Curigliano et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
- (2009) Marc Spielmann et al. JOURNAL OF CLINICAL ONCOLOGY
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller
- (2009) Ana M. Gonzalez-Angulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
- (2009) Heikki Joensuu et al. JOURNAL OF CLINICAL ONCOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer
- (2008) Chau Dang et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
- (2008) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started